CA2612690C - Detection specifique de la methylation - Google Patents

Detection specifique de la methylation Download PDF

Info

Publication number: CA2612690C
Authority: CA; Canada
Prior art keywords: methylated; dna; methylation; unmethylated; msp
Prior art date: 1996-06-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2612690A

Other languages

English (en)

Other versions

CA2612690A1 (fr

Inventor

James G. Herman

Stephen B. Baylin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Johns Hopkins University

Original Assignee

Johns Hopkins University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-03

Filing date

1997-06-03

Publication date

2012-04-24

1996-06-03 Priority claimed from US08/656,716 external-priority patent/US5786146A/en

1997-04-11 Priority claimed from US08/835,728 external-priority patent/US6017704A/en

1997-06-03 Application filed by Johns Hopkins University filed Critical Johns Hopkins University

1997-12-11 Publication of CA2612690A1 publication Critical patent/CA2612690A1/fr

2012-04-24 Application granted granted Critical

2012-04-24 Publication of CA2612690C publication Critical patent/CA2612690C/fr

2017-06-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000011987 methylation Effects 0.000 title claims abstract description 91
238000007069 methylation reaction Methods 0.000 title claims abstract description 91
238000011895 specific detection Methods 0.000 title description 2
238000000034 method Methods 0.000 claims abstract description 77
150000007523 nucleic acids Chemical class 0.000 claims abstract description 53
102000039446 nucleic acids Human genes 0.000 claims abstract description 52
108020004707 nucleic acids Proteins 0.000 claims abstract description 52
210000004027 cell Anatomy 0.000 claims description 81
108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 46
239000000523 sample Substances 0.000 claims description 38
210000001519 tissue Anatomy 0.000 claims description 31
108091008146 restriction endonucleases Proteins 0.000 claims description 22
102000004190 Enzymes Human genes 0.000 claims description 18
108090000790 Enzymes Proteins 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
239000003153 chemical reaction reagent Substances 0.000 claims description 16
230000006607 hypermethylation Effects 0.000 claims description 15
239000013060 biological fluid Substances 0.000 claims description 13
230000002062 proliferating effect Effects 0.000 claims description 12
206010036790 Productive cough Diseases 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 7
210000003802 sputum Anatomy 0.000 claims description 7
208000024794 sputum Diseases 0.000 claims description 7
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 5
239000002853 nucleic acid probe Substances 0.000 claims description 5
102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 claims description 4
210000004369 blood Anatomy 0.000 claims description 4
239000008280 blood Substances 0.000 claims description 4
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
239000007850 fluorescent dye Substances 0.000 claims description 4
210000003296 saliva Anatomy 0.000 claims description 4
210000002966 serum Anatomy 0.000 claims description 4
229910052751 metal Inorganic materials 0.000 claims description 3
239000002184 metal Substances 0.000 claims description 3
210000002700 urine Anatomy 0.000 claims description 3
239000013522 chelant Substances 0.000 claims 2
238000007855 methylation-specific PCR Methods 0.000 abstract description 76
238000006243 chemical reaction Methods 0.000 abstract description 31
238000001514 detection method Methods 0.000 abstract description 30
230000035945 sensitivity Effects 0.000 abstract description 9
230000007067 DNA methylation Effects 0.000 abstract description 7
239000013615 primer Substances 0.000 description 132
108020004414 DNA Proteins 0.000 description 114
206010028980 Neoplasm Diseases 0.000 description 52
108090000623 proteins and genes Proteins 0.000 description 52
102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 41
230000003321 amplification Effects 0.000 description 39
238000003199 nucleic acid amplification method Methods 0.000 description 39
238000004458 analytical method Methods 0.000 description 35
102100033254 Tumor suppressor ARF Human genes 0.000 description 31
108700028369 Alleles Proteins 0.000 description 28
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 28
201000011510 cancer Diseases 0.000 description 26
238000012163 sequencing technique Methods 0.000 description 26
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 24
108091029523 CpG island Proteins 0.000 description 23
-1 GST-pi Proteins 0.000 description 16
239000003795 chemical substances by application Substances 0.000 description 16
229940088598 enzyme Drugs 0.000 description 16
108091029430 CpG site Proteins 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 14
230000004048 modification Effects 0.000 description 14
238000012986 modification Methods 0.000 description 14
108700039691 Genetic Promoter Regions Proteins 0.000 description 13
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 13
208000035475 disorder Diseases 0.000 description 13
239000000203 mixture Substances 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
230000000295 complement effect Effects 0.000 description 11
230000014509 gene expression Effects 0.000 description 11
108700025716 Tumor Suppressor Genes Proteins 0.000 description 10
102000044209 Tumor Suppressor Genes Human genes 0.000 description 10
208000029742 colonic neoplasm Diseases 0.000 description 10
206010058467 Lung neoplasm malignant Diseases 0.000 description 9
230000000692 anti-sense effect Effects 0.000 description 9
239000000499 gel Substances 0.000 description 9
201000005202 lung cancer Diseases 0.000 description 9
208000020816 lung neoplasm Diseases 0.000 description 9
239000002773 nucleotide Substances 0.000 description 9
125000003729 nucleotide group Chemical group 0.000 description 9
238000006116 polymerization reaction Methods 0.000 description 9
102000040430 polynucleotide Human genes 0.000 description 9
108091033319 polynucleotide Proteins 0.000 description 9
239000002157 polynucleotide Substances 0.000 description 9
102000000905 Cadherin Human genes 0.000 description 8
108050007957 Cadherin Proteins 0.000 description 8
101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 8
238000013459 approach Methods 0.000 description 8
238000003556 assay Methods 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
238000003018 immunoassay Methods 0.000 description 8
102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 7
239000000872 buffer Substances 0.000 description 7
108010038795 estrogen receptors Proteins 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
230000002103 transcriptional effect Effects 0.000 description 7
206010009944 Colon cancer Diseases 0.000 description 6
239000003155 DNA primer Substances 0.000 description 6
101001081170 Homo sapiens Humanin-like 12 Proteins 0.000 description 6
102100027737 Humanin-like 12 Human genes 0.000 description 6
102100031612 Hypermethylated in cancer 1 protein Human genes 0.000 description 6
101710133850 Hypermethylated in cancer 1 protein Proteins 0.000 description 6
238000012408 PCR amplification Methods 0.000 description 6
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 6
210000001072 colon Anatomy 0.000 description 6
102000015694 estrogen receptors Human genes 0.000 description 6
238000007901 in situ hybridization Methods 0.000 description 6
239000003550 marker Substances 0.000 description 6
238000011160 research Methods 0.000 description 6
239000007787 solid Substances 0.000 description 6
229940035893 uracil Drugs 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 5
101710136552 Fatty acid-binding protein, heart Proteins 0.000 description 5
208000032818 Microsatellite Instability Diseases 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
238000002105 Southern blotting Methods 0.000 description 5
238000007385 chemical modification Methods 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000011065 in-situ storage Methods 0.000 description 5
230000002779 inactivation Effects 0.000 description 5
230000035772 mutation Effects 0.000 description 5
108700042657 p16 Genes Proteins 0.000 description 5
229920002401 polyacrylamide Polymers 0.000 description 5
230000008569 process Effects 0.000 description 5
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
102000055006 Calcitonin Human genes 0.000 description 4
108060001064 Calcitonin Proteins 0.000 description 4
108010017826 DNA Polymerase I Proteins 0.000 description 4
102000004594 DNA Polymerase I Human genes 0.000 description 4
102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 4
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 4
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 4
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
229910015837 MSH2 Inorganic materials 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
108010026664 MutL Protein Homolog 1 Proteins 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
208000006265 Renal cell carcinoma Diseases 0.000 description 4
108010006785 Taq Polymerase Proteins 0.000 description 4
230000001594 aberrant effect Effects 0.000 description 4
239000000427 antigen Substances 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
230000008901 benefit Effects 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
229960004015 calcitonin Drugs 0.000 description 4
230000008859 change Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
229940104302 cytosine Drugs 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000012634 fragment Substances 0.000 description 4
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
230000001613 neoplastic effect Effects 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
230000007017 scission Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
102100032187 Androgen receptor Human genes 0.000 description 3
102000052609 BRCA2 Human genes 0.000 description 3
108700020462 BRCA2 Proteins 0.000 description 3
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
101150008921 Brca2 gene Proteins 0.000 description 3
208000005623 Carcinogenesis Diseases 0.000 description 3
102000013128 Endothelin B Receptor Human genes 0.000 description 3
108010090557 Endothelin B Receptor Proteins 0.000 description 3
101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 description 3
208000008839 Kidney Neoplasms Diseases 0.000 description 3
108060004795 Methyltransferase Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 3
108010080146 androgen receptors Proteins 0.000 description 3
238000000137 annealing Methods 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
230000036952 cancer formation Effects 0.000 description 3
231100000504 carcinogenesis Toxicity 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
230000030279 gene silencing Effects 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
238000013507 mapping Methods 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
241000972773 Aulopiformes Species 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
102000001218 Rec A Recombinases Human genes 0.000 description 2
108010055016 Rec A Recombinases Proteins 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
108091005735 TGF-beta receptors Proteins 0.000 description 2
102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 2
108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 2
102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000003850 cellular structure Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000002059 diagnostic imaging Methods 0.000 description 2
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
238000002595 magnetic resonance imaging Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
230000005298 paramagnetic effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
239000001226 triphosphate Substances 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
GHKCSRZBNZQHKW-UWTATZPHSA-N (1R)-1-sulfanylethanol Chemical compound C[C@H](O)S GHKCSRZBNZQHKW-UWTATZPHSA-N 0.000 description 1
BAAVRTJSLCSMNM-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 BAAVRTJSLCSMNM-CMOCDZPBSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
GPLIMIJPIZGPIF-UHFFFAOYSA-N 2-hydroxy-1,4-benzoquinone Chemical compound OC1=CC(=O)C=CC1=O GPLIMIJPIZGPIF-UHFFFAOYSA-N 0.000 description 1
108020005065 3' Flanking Region Proteins 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
108020005029 5' Flanking Region Proteins 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
108091033380 Coding strand Proteins 0.000 description 1
108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 1
102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
230000007018 DNA scission Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000004435 EPR spectroscopy Methods 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
208000001914 Fragile X syndrome Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
101000954986 Homo sapiens Merlin Proteins 0.000 description 1
208000035346 Margins of Excision Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
102100037106 Merlin Human genes 0.000 description 1
241000087624 Monoclona Species 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
102000007530 Neurofibromin 1 Human genes 0.000 description 1
108010085793 Neurofibromin 1 Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
208000007660 Residual Neoplasm Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
108700025701 Retinoblastoma Genes Proteins 0.000 description 1
102100022828 Retinoblastoma-like protein 2 Human genes 0.000 description 1
108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
101150046474 Vhl gene Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
108700031765 Von Hippel-Lindau Tumor Suppressor Proteins 0.000 description 1
210000001766 X chromosome Anatomy 0.000 description 1
108700029631 X-Linked Genes Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical class CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229960001570 ademetionine Drugs 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
206010002224 anaplastic astrocytoma Diseases 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000004568 cement Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000007806 chemical reaction intermediate Substances 0.000 description 1
230000002113 chemopreventative effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000001246 colloidal dispersion Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000002967 competitive immunoassay Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000007911 de novo DNA methylation Effects 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000005549 deoxyribonucleoside Substances 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
238000012226 gene silencing method Methods 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
238000003505 heat denaturation Methods 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000013198 immunometric assay Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000007850 in situ PCR Methods 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
208000022080 low-grade astrocytoma Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
230000005291 magnetic effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
230000033607 mismatch repair Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000005382 thermal cycling Methods 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000037426 transcriptional repression Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
108010032276 tyrosyl-glutamyl-tyrosyl-glutamic acid Proteins 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
239000013598 vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Landscapes

Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA2612690A 1996-06-03 1997-06-03 Detection specifique de la methylation Expired - Lifetime CA2612690C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US08/656,716 US5786146A (en)	1996-06-03	1996-06-03	Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US08/656,716		1996-06-03
US08/835,728		1997-04-11
US08/835,728 US6017704A (en)	1996-06-03	1997-04-11	Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
CA002257104A CA2257104C (fr)	1996-06-03	1997-06-03	Detection specifique de la methylation

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002257104A Division CA2257104C (fr)	1996-06-03	1997-06-03	Detection specifique de la methylation

Publications (2)

Publication Number	Publication Date
CA2612690A1 CA2612690A1 (fr)	1997-12-11
CA2612690C true CA2612690C (fr)	2012-04-24

Family

ID=39133643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2612690A Expired - Lifetime CA2612690C (fr)	1996-06-03	1997-06-03	Detection specifique de la methylation

Country Status (1)

Country	Link
CA (1)	CA2612690C (fr)

1997
- 1997-06-03 CA CA2612690A patent/CA2612690C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2612690A1 (fr)	1997-12-11

Legal Events

Date	Code	Title	Description
2008-05-02	EEER	Examination request
2017-08-07	MKEX	Expiry	Effective date: 20170605

Publication	Publication Date	Title
EP0954608B1 (fr)	2006-05-17	Detection specifique de la methylation
US6200756B1 (en)	2001-03-13	Methods for identifying methylation patterns in a CpG-containing nucleic acid
EP0672181B1 (fr)	2003-11-05	Procedes de detection d'acides nucleiques de mammifere isoles a partir d'un echantillon de selles, et reactifs utilises a cet effet
CA2422890C (fr)	2013-04-23	Methode de prediction de la reaction clinique a un traitement chimiotherapeutique avec des agents alkylants
US7485418B2 (en)	2009-02-03	Aberrantly methylated genes in pancreatic cancer
JP2017060474A (ja)	2017-03-30	結腸直腸がんのエピジェネティックマーカー及び該マーカーを使用する診断法
JP2005204652A (ja)	2005-08-04	メチル化特異的プライマー伸長（ｍｓｐｅ）によるメチル化状況を検出するアッセイ
US20030190616A1 (en)	2003-10-09	Differentially methylated sequences in pancreatic cancer
WO2018211404A1 (fr)	2018-11-22	1 biomarqueurs épigénétiques composites pour criblage, diagnostic et pronostic précis du cancer colorectal
CN113249471A (zh)	2021-08-13	一种用于检测肝癌的生物标志物组合
CA2612690C (fr)	2012-04-24	Detection specifique de la methylation
CN120989247A (zh)	2025-11-21	用于检测肺癌的组合物及其用途
TW202338101A (zh)	2023-10-01	用於檢測膀胱癌之存在之引子及探針
AU774182B2 (en)	2004-06-17	Automatable rapid test for detecting cancers, on the basis of telomerase(hTC) mRNA and specific primers and probes